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Abstract  
Overweight and obesity are well-established risk factors for most cardiovascular diseases (CVD), 
including coronary heart disease (CHD), heart failure (HF), and atrial fibrillation. Despite the strong link 
between excess adiposity and risk of CVD, growing evidence has demonstrated an obesity paradox in 
patients with CVD. This phenomenon is characterized by a better prognosis in overweight and mildly 
obese CVD patients than their leaner counterparts. Moreover, the worst outcomes are often incurred by 
underweight CVD patients, followed by those of normal weight or severely obese. The obesity paradox is 
now a well-established phenomenon across different types of CVD, and it occurs regardless of age and 
ethnicity of patients, and severity of CVD. Physical inactivity and low cardiorespiratory fitness (CRF) have 
long been recognized as major risk factors for CVD. In contrast, high levels of physical activity (PA) and 
CRF largely neutralize the adverse effects of excess adiposity and other traditional CVD risk factors, 
including hypertension, metabolic syndrome, and type-2 diabetes. Higher CRF also results in better CVD 
outcomes across different BMI groups and significantly alters the obesity paradox in patients with HF 
and CHD. Prognostic benefits of overweight/obesity tend to be limited to unfit patients with HF and 
CHD, and the obesity paradox usually disappears with improved levels of CRF. Nevertheless, increased 
PA and exercise training, to maintain or improve CRF, are effective, safe, and proven strategies for 
primary and secondary prevention of CVD in all weight groups. In this review, we discuss the current 
concepts of individual and combined contributions of fatness and fitness to CVD risk and prognosis.  We 
then examine the influence of fitness on the obesity paradox in individuals with CVD. 
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Abbreviations 
ACLS = Aerobics Centers Longitudinal Study        T2DM = Type-2 diabetes mellitus 
ACS = Acute coronary syndrome         VA =Veterans affairs 
AF = Atrial fibrillation           VO2max = Maximal oxygen consumption 
BMI = Body mass index           WC = Waist circumference 
CAC = Coronary artery calcium         %BF = Percent body fat 
CCLS = Cooper Center Longitudinal Study 
CHD = Coronary heart disease 
CKD = Chronic kidney disease 
CPX = Cardiopulmonary exercise testing 
CRF = Cardiorespiratory fitness 
CV = Cardiovascular 
CVD = Cardiovascular disease 
DM = Diabetes mellitus 
ET= Exercise training 
FHS = Framingham heart study 
HF = Heart failure 
HFpEF = Heart failure with preserved ejection fraction 
HFrEF = Heart failure with reduced ejection fraction 
HTN = Hypertension 
LA = Left atrial 
LV = Left ventricular 
LVH =Left ventricular hypertrophy 
MET = Metabolic equivalent 
MS = Metabolic syndrome 
MI = Myocardial infarction 
PA = Physical activity 
6MWD = Six-minute walk distance 
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Overweight and obesity are well-established risk factors for cardiovascular disease (CVD) and 
mortality. Numerous studies have confirmed the strong association of overweight and obesity with 
increased prevalence of most CVDs, including coronary heart disease (CHD), atrial fibrillation (AF) and 
heart failure (HF).1–4 Two main factors underlie the excess risk of CVD in obesity. 1) Obesity shows strong 
association with other major CVD risk factors, such as hypertension (HTN), atherosclerosis, metabolic 
syndrome (MS), type-2 diabetes mellitus (DM; T2DM), dyslipidemia and obstructive sleep apnea. 2) 
Increased adiposity can independently induce alterations in the cardiac structure and function.5,6 
Despite the strong relationship between obesity and development of CVD, multiple studies, mostly 
published in the last 15 years, have demonstrated an ‘obesity paradox,' which is characterized by a 
better short- and intermediate-term prognosis in overweight or mildly obese patients with CVD 
compared to their leaner or normal-weight counterparts.5–8 
The global epidemic of obesity has mainly been attributed to poor dietary choices characterized 
by excessive calorie intake9,10 and to massive declines in occupational physical activity (PA) in both men 
and women and household management in women during past decades.11,12 Moreover, numerous 
studies assessing occupational and leisure-time PA, and cardiorespiratory fitness (CRF) have revealed a 
strong, inverse, graded and independent association of PA/CRF with both CVD and overall mortality, 
regardless of race and gender.13 Physical inactivity and low CRF are now recognized as major risk factors 
for CVD and stroke.14,15 Moreover, improved CRF has been linked to better prognosis and lower risk of 
mortality after the onset of CVDs.13   
The relative and joint contributions of fatness and fitness to health remain poorly understood. 
But, growing evidence suggests that improved CRF largely neutralizes the adverse effects of increased 
adiposity, as well as other traditional CVD risk factors, including HTN, MS, and T2DM.8,16–18 
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In this review, we discuss the current concepts of individual and combined contributions of 
fatness and fitness to CVD risk and prognosis.  We then examine the relationship between CRF and the 
obesity paradox in individuals with CVD.  
Obesity as a Risk Factor for CVD and Mortality 
 Weight gain and obesity lead to various alterations in the central and peripheral hemodynamics, 
including increased total and central blood volume, decreased systemic vascular resistance, and a rise in 
left ventricular (LV) stroke volume, cardiac output, LV filling pressures and pulmonary artery pressures.5–
7,19  A complex interaction between these hemodynamic alterations and several other mechanisms, such 
as HTN, neurohormonal and metabolic abnormalities results in cardiac remodeling and dysfunction in 
obesity.20 Obese individuals are more likely to have LV remodeling (concentric remodeling and LV 
hypertrophy[LVH]), left atrial (LA) enlargement, and greater right ventricular mass and end-diastolic 
volume.21–24 Furthermore, obesity has been associated with LV diastolic dysfunction, subclinical LV 
systolic dysfunction (low myocardial strain), and reduced right ventricular ejection fraction.6,25–28   
 Mortality: In the general population, the association between BMI and risk of mortality is non-
linear, and it usually follows a U-shaped pattern. There exists a significant variation among 
epidemiologic studies regarding what constitutes a ‘healthy’ BMI. A meta-analysis of 230 cohort studies 
with a combined sample size of 30.3 million participants reported higher risk of mortality in 
underweight, overweight and obese individuals.29 In the analysis of all participants, the lowest risk of 
mortality was observed among those with a BMI around 25, while among never smokers those with a 
BMI of 23-24 had the lowest risk of mortality. A recent study by Afzal et al. has broadened our 
understanding of ‘healthy’ BMI and its dynamic nature.30 The investigators compared the BMI-mortality 
relationships from 3 different Danish cohorts enrolled at different times over the past three decades. 
The study revealed that the BMI value associated with the nadir of all-cause mortality risk increased by 
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3.3 kg/m2 (from 23.7 to 27 kg/m2) from 1976 to 2003-2013. Moreover, over the past three decades, the 
hazard-ratio of all-cause mortality related to BMI ≥30 vs. BMI of 18.5 to 24.9 kg/m2 decreased from 1.3 
to 1.0.   
 HF: Multiple epidemiological studies have demonstrated a strong association between 
overweight/obesity and HF. In the Framingham Heart Study (FHS), every 1 kg/m2 increment in BMI was 
found to increase the risk of HF by 5% in men and 7% in women.3 Other obesity parameters, such as 
waist circumference (WC) or waist-to-hip ratio, also predict the risk of future HF. In a meta-analysis of 28 
prospective studies (>600.000 participants), every 10 cm increase in WC was associated with a 29% 
higher risk of HF.31 Obesity tends to show a stronger association with HF with preserved ejection fraction 
(HFpEF) than HF with reduced ejection fraction (HFrEF).32,33 Pandey et al., using data from 3 major 
cohort studies (N=51,451), recently demonstrated that higher BMI had a strong dose-dependent 
association with the cumulative incidence of only HFpEF but not HFrEF.34 
 CHD: Obesity and related comorbidities such as HTN, T2DM, dyslipidemia, systemic 
inflammation play a significant role in the pathogenesis of atherosclerosis, the hallmark finding of CHD.35 
Consistently, overweight and obese individuals tend to have a higher prevalence of CHD compared to 
their leaner counterparts.36 Data from the FHS demonstrated after adjustment for other covariates that 
approximately 23% of CHD in men and 15% of CHD in women were attributable to excess adiposity.4 
Acute coronary syndromes (ACS) occur at earlier ages in overweight and obese individuals compared to 
those with a normal BMI. A large retrospective cohort study (n=111,847) showed that the age at first 
non-ST-elevation myocardial infarction (MI) in individuals with grade 1, grade 2 or grade 3 obesity were 
6.8, 9.4, 12.0 years earlier, respectively, compared to that in normal weight patients.37 The independent 
impact of obesity on the risk of ACS has not been consistently confirmed across epidemiologic studies. 
For example, a large population-based cohort study (n= 61,299 and 12 years of follow-up) from Norway 
found that obese and metabolically healthy individuals did not have excess risk of MI when compared 
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with normal weight and metabolically healthy individuals.38 However, these results were challenged by 
two meta-analyses which showed that overweight and obese individuals are at increased risk of CVD 
and mortality even in the absence of metabolic abnormalities.39,40 
 AF: There exists substantial evidence on the relationship between obesity and risk of AF. In a 
meta-analysis of 16 studies with a combined sample size >123,000, obesity was associated with ~50% 
higher risk of AF than normal weight.41 Among the FHS participants, every 1-unit increase in BMI was 
found to increase the risk of AF by 4%.42 Studies with a longer duration of follow-up period have 
revealed a more obvious relation between obesity and AF risk. A population-based cohort study 
(n=12,850) with a median follow-up period of 26 years demonstrated that compared to their normal 
weight counterparts, overweight and obese young men had 2-fold and 3-fold increased risk of future AF, 
respectively.1 Moreover, increased BMI strongly predicts the risk of progression from paroxysmal AF to 
permanent AF.43 
Obesity Paradox in CVD 
 Despite the strong relation between excess adiposity and development of CVDs, a large body of 
evidence has demonstrated an obesity paradox in patients with CVD. This phenomenon is characterized 
by a better prognosis in overweight and mildly obese patients with CVD, compared to their leaner 
counterparts. Also, the worst outcomes are usually observed in underweight CVD patients, followed by 
those with normal weight or severe obesity.5,6 The obesity paradox in CVD derives from a complex 
interaction between several potential mechanisms (Table). Relative contribution of each mechanism to 
the obesity paradox remains poorly understood. However, growing evidence suggest that muscle mass 
and strength and CRF are the major determinants of the prognostic implications of obesity in CVD.44–47     
HF: The obesity paradox is a well-established phenomenon in patients with HF. It is observed 
across different ethnicities and regardless of the acuity (acute vs. chronic), etiology (ischemic vs. non-
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ischemic), type (HFpEF vs. HFrEF), and severity (advanced vs. non-advanced) of HF.6–8,48 Several studies 
have suggested a U-curve shaped relationship between BMI and adverse outcomes in HF.49–51 For 
instance, the poorest prognosis was usually reported in underweight HF patients and to a lesser extent 
in severely obese ones and a nadir of risk with overweight and mild obesity. The protective effect of 
obesity is often lost in severely obese HF patients. Nagarajan et al. found in 501 consecutive patients 
with advance HF that a BMI of ≥40 kg/m2 was associated with 2.5-times higher risk of mortality 
compared to a BMI of 30.1 to 39.9 kg/m2.52 Some studies, but not all, suggested a sex-specific 
interaction between obesity and prognosis in HF. A retrospective cohort study by Vest et al. in 3,811 
mostly advanced HF patients demonstrated an obesity paradox in regards to all-cause mortality with the 
unadjusted data.50 However, when the authors adjusted the results for other confounders (including CRF 
and other variables), the overweight/obesity survival benefit only remained significant in female 
patients. Only a few studies have examined the impact of obesity parameters other than BMI on HF 
prognosis. Clark et al. reported the best survival in HF patients with high BMI and high WC and the worst 
prognosis in those with normal BMI and normal WC.53,54 
CHD: In a meta-analysis of 40 studies and >250,000 patients with CHD, Romero-Corral et al. 
reported more favorable CV and total mortality outcomes in overweight and mildly obese patients than 
those of normal weight and underweight groups.55 These results were confirmed by another meta-
analysis with a larger sample size (89 studies, 1.3 million patients with CHD).56 In this study, overweight 
and obesity were associated with lower risk of short-term (<6 months) and long-term (≥6 months) 
mortality. However, the survival benefit of obesity in CHD was lost after five years. Moreover, patients 
with grade II/III obesity had a lower risk of short-term mortality, but higher risk of long-term mortality. 
Several studies examined the relative and combined prognostic implications of BMI and other adiposity 
parameters in patients with CHD. In a systematic review of 6 studies with nearly 16,000 subjects, BMI 
was inversely correlated with mortality.57 However, central obesity was a predictor of higher mortality 
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even in normal weight (BMI<25 kg/m2) individuals. A similar analysis in patients with CHD reported the 
highest risk of mortality in normal weight subjects with central obesity compared with subjects with 
other weight patterns.58 
 AF: An obesity paradox exists for outcomes in AF as well. A post hoc analysis of the Atrial 
Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study (n=2,492) demonstrated 
lower risk of mortality in overweight and obese AF patients compared with the normal weight ones.59 
Similar results were observed in regards to CVD and all-cause mortality among Japanese patients with 
non-valvular AF and a contemporary cohort of outpatients with AF in the US.60,61 Sandhu et al. recently 
reported a post hoc analysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events 
in Atrial Fibrillation (ARISTOTLE) trial which examined the impact of BMI and WC on outcomes in AF 
patients (n=17,913).62 The study revealed an inverse association between BMI and risk of all-cause 
mortality and the composite end-point, which included stroke, systemic embolism, MI, and all-cause 
mortality. Interestingly, WC had an inverse relationship with adverse outcomes in women, but not in 
men. 
CRF and Risk of CVD and Mortality  
 Physical inactivity and low CRF are well-recognized risk factors for CVD.14,63–65 Mainly because of 
the simplicity of data-collection, self-reported PA has been the most commonly studied indicator of CRF. 
However, it should be noted that PA and fitness are two closely-related measures with very distinct 
definitions. PA refers to a collection of behaviors with several domains such as occupational, domestic, 
transportation, and leisure-time PA.14 In contrast, CRF is a health-related component of physical fitness, 
and it is defined as the ability of the respiratory, circulatory and muscular systems to supply oxygen 
during sustained PA.66 In simple terms, high CRF indicates the presence of highly integrated and well-
functioning oxygen transport and utilization systems. An individual’s CRF is determined by an interaction 
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of several factors, such as PA, age, sex, ethnicity, muscle mass, adiposity, genetics, and CV and 
respiratory health.67 Moreover, PA and ET can modify CRF, and improvements in CRF predict lower risk 
of mortality.68 CRF is ideally measured by cardiopulmonary exercise testing (CPX) which requires 
specialized laboratory equipment and trained personnel. CRF is usually reported as metabolic 
equivalents (METs) or maximal oxygen consumption (VO2max, ml O2/kg.min).
67 In clinical practice and 
research studies, several other techniques are commonly used as surrogates for CRF assessment, such 
as 6-minute walk test and exercise tolerance on a regular treadmill test.  
 Increased CRF has been associated with lower blood pressure levels and delay and prevention of 
development of HTN.69,70 Moreover, it leads to an improvement in other cardiometabolic risk factors 
and MS components.71,72 Higher CRF has been associated with several changes in the CV structure and 
function, such as larger LV chamber size, less concentric LV remodeling, lower estimated LV filling 
pressures, improved diastolic function, greater LA volume.73,74 Data from the FHS revealed that higher 
PA levels measured by accelerometer were associated with lower arterial stiffness and greater LV mass, 
aortic root, and LA size.75 In the Coronary Artery Risk Development in Young Adults (CARDIA) study 
higher baseline CRF was associated with favorable global longitudinal strain, better diastolic function, 
and lower LV mass even after 25 years of follow-up.76,77 Consistently, regular exercise can result in 
regression of LVH findings on echocardiography.78 
 Mortality: Numerous studies have confirmed the strong, inverse and graded relationship of PA 
and CRF levels with lower risk of CVD morbidity and mortality, and overall mortality in apparently 
healthy individuals or those with documented CVD. In general, high CRF provides a protective effect 
regardless of race, age and gender, and independent of other traditional risk factors, including smoking, 
DM, HTN, BMI and lipid panel.13,67,79 Interestingly, in many circumstances, individuals with high CRF and 
CVD risk factors or CVD have better survival than their counterparts without these conditions but with 
low CRF.48  Almost 3 decades ago, Blair et al. in their landmark study (n=13,354, follow-up >8 years) 
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demonstrated that higher CRF estimated with treadmill exercise test was a strong and independent 
predictor of lower risk of all-cause and CVD mortality in both men and women.80 In a meta-analysis of 33 
studies with a combined sample size over 100,000 participants (with no known CHD and major risk 
factors at baseline), Kodama et al. demonstrated that every 1-MET increase in CRF was associated with 
13% and 15% reduction in all-cause and CVD mortality, respectively.81 Higher levels of CRF have also 
been linked to lower risk of fatal and non-fatal stroke and death from cancer, independent of obesity 
measures.82,83 In the Cooper Center Longitudinal Study (CCLS) with over 60,000 participants with no 
known CVD at baseline, the addition of a single measure of CRF to other traditional CVD risk factors 
resulted in a significant improvement in both 10-year and 25-year risk classification for CVD mortality.84 
Maintenance and improvement of CRF levels carry significance from a prognostic standpoint.85 In the 
Aerobics Centers Longitudinal Study (ACLS), individuals who maintained or improved their CRF over a 
period of 6.3 years were found to have a lower risk of all-cause and CVD mortality compared to those 
with a loss in their CRF.86 Moreover, the association between changes in weight and risk of all-cause, 
and CVD mortality became insignificant after adjusting for potential confounders and alterations in CRF.  
Several reports have suggested that the greatest benefits of risk reduction are achieved with 
transitioning from a sedentary lifestyle to modest amounts of exercise or from the lowest levels of CRF 
to the next highest CRF.67  In a large prospective observational cohort study (>55,000 participants 
without documented CVD, 15 years of follow-up), Lee et al. found marked reduction in the risk of death 
from all causes and CVD with leisure-time running even at low doses (5 to 10 minutes/day) and speed 
(<6 miles/h).87 
HF: Recent studies have demonstrated a dose-dependent inverse association between levels of 
leisure-time PA and HF risk.34,64 Reports from CCLS showed that high levels of objectively measured CRF 
in mid-life predicts a significantly lower risk of HF hospitalizations and mortality later in old age.88,89 
Furthermore, this protective effect of CRF on HF risk is modifiable and independent of antecedent 
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burden of traditional cardiovascular risk factors90 and likely related to favorable effects of CRF on the 
cardiac structure and function.77 Similarly, a prospective cohort study from Finland (n=1,853 men 
without HF at baseline, mean follow-up of 20.3 years) reported 21% reduction in risk of multivariable 
adjusted risk of new-onset HF with every 1-MET increment in the baseline CRF.91 Moreover, several CPX 
parameters such as VO2max and the slope of minute ventilation/carbon dioxide production (a measure 
of ventilatory efficiency) independently predict outcomes in patients with established HF.19,92 Adjusted 
VO2max of <14 mL/kg.min has long been recognized as a relative indication for heart transplantation in 
patients with advanced HF.93 
CHD: Gander et al., using data from the ACLS, demonstrated that CRF is an independent 
determinant for future CHD risk even after controlling for a well-established CHD risk calculator, such as 
the Framingham Risk Score.94 The investigators found that CHD incidence decreases by 20% with each 1-
unit increase in the maximally achieved MET. In some but not all studies, low baseline CRF levels were 
found to predict incident coronary artery calcification (CAC), a finding of subclinical atherosclerosis.76,95 
Moreover, low CRF has been independently associated with CVD events, even after adjustment for CAC 
detected by computed tomography.96  
 AF: Increasing PA and higher CRF have been shown to reduce the incidence of AF. However, the 
relationship between PA and AF appear to follow a U-shaped pattern with a possible increase in the AF 
rate with the highest levels of PA.97 Mozaffarian et al., in a population-based prospective study of 5,446 
older adults, demonstrated a graded inverse relationship between leisure-time PA and incident AF.98  
Another population-based study which included >36,000 AF-free Swedish women at baseline found that 
moderate amount of exercise (≥4h/week) compared to minimal to no exercise (<1h/week) was linked to 
a 15% lower risk of new-onset AF after 12 years of follow-up.99 A retrospective cohort study of nearly 
70,000 adults who underwent physician-referred treadmill testing demonstrated that every 1-MET 
increment in the CRF at baseline was associated with a 7% lower risk of AF during a median follow-up of 
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5.4 years.100 In this study, the protective effect of higher CRF was more pronounced in obese and older 
individuals. The inverse relationship between higher CRF and incident AF was also confirmed in other 
studies using VO2max to estimate CRF.
101  
CRF also significantly affects the risk of arrhythmia recurrence in patients with AF. In a 
prospective study of 1,415 AF patients enrolled in a tailored exercise program, Pathak et al. observed 
that every 1-MET increase in baseline CRF reduced the risk of arrhythmia recurrence by 20%.102 The 
degree of CRF gain from the baseline fitness during exercise program was a predictor of decreased risk 
of arrhythmia recurrence. Moreover, the protective effect of CRF gain was augmented when 
participants achieved ≥10% weight loss (Figure 1).  
Contribution of Veterans Affairs (VA) Cohort Studies  
The majority of epidemiologic studies on CRF from several institutions and different parts of the 
US and the world include middle-aged and relatively healthy cohorts. In addition, many of these cohorts 
lack data on comorbidities and medications of the participants. In this regard, several relatively large 
prospective epidemiologic studies from the Washington, DC and Palo Alto, CA VA Medical Centers have 
filled this void. These studies mostly consist of middle-aged or older veterans referred for an exercise 
tolerance test for clinical reasons. The equal access to care provided by the Veterans Health 
Administration independent of a patient’s financial status, a unique feature of this cohort, permits 
epidemiological evaluations while minimizing the influence of disparities in medical care. Moreover, the 
existence of well-established electronic health records within the VA Healthcare System enables 
detailed observation of prior history, comorbidities, medications, and alterations in health status. These 
attributes, coupled with the ability to consider conditions with high short-term mortality rates such as 
muscle-wasting disease, minimize the possibility of reverse causality, and support the validity of the CRF 
and mortality relationship for all ages and the age-specific exercise thresholds for risk assessment. 
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 In general, these studies have strongly confirmed the preventive and therapeutic aspects of CRF. 
For example, they have shown that the incidence of HTN is inversely related to CRF and fit veterans have 
markedly reduced rate of progression from pre-HTN to HTN.103 Similarly, chronic kidney disease (CKD) 
incidence was 22% lower for every 1-MET increase in exercise capacity and this translated into 40% to 
60% less risk of CKD in moderate-fit (peak METs achieved 6.5) and high-fit (peak METs achieved 7.7) 
individuals compared to the least-fit (peak MET level achieved 4.8).104 The incidence of AF was also 
significantly and progressively attenuated by 20% to 63% for veterans with an exercise capacity ≥7.0 
METs.105 Finally, in over 20,500 veterans free from CVD at the time of the exercise testing, the risk of 
having a major CVD event was 16% lower for each 1-MET increase in exercise capacity and was 30% to 
68% lower for those with an exercise capacity ≥6 METs (Figure 2).106 In a separate study, the incidence of 
HF in a group of more than 20,000 veterans free of HF at baseline, adding CRF status to traditional risk 
factors resulted in reclassification of HF risk in 37% of the participants.107 
 VA-based studies have also confirmed the independent, inverse and graded association 
between CRF and CVD79,106,107 and all-cause mortality in both blacks and whites108,109 and those with 
specific comorbidities such as HTN,110,111 pre-HTN,112 T2DM,109,113 dyslipidemia,114,115 and obesity.116 They 
have also established an age-specific fitness classification and age-specific CRF/MET threshold that can 
be used to classify CRF categories and risk association more precisely and that are unique to veterans.117 
In hypertensive veterans, mortality risk was cut by approximately 50% to 70% for those with a peak MET 
level >7 METs regardless of 2 or more additional risk factors.110 In veterans with T2DM, the exercise 
capacity-mortality risk association was inverse, independent, and graded.109,113 When considering BMI, 
the inverse and graded association was evident in all BMI categories. But the impact of CRF was more 
potent in those with a BMI ≥25 kg/m2.  
The interactive effects of statins and CRF were also assessed in over 10,000 dyslipidemic 
veterans.  Increased CRF was inversely and independently associated with mortality risk in veterans 
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treated (n=5,033) and not treated (n=5,010) with a statin. Interestingly, survival benefits of CRF were 
similar to those observed with statin therapy. When increased CRF and statin therapy were combined, 
survival benefits were additive.115 Similarly, the mortality risk reduction associated with moderate 
increases in CRF was similar to that achieved by statin therapy in veterans with dyslipidemia and HTN.114 
In diabetic veterans, statin therapy also resulted in improved survival, which was further enhanced 
when increased CRF fitness and statin therapy were combined.118  
Interaction of CRF and Obesity 
 A complex interplay between fitness and fatness contribute to an individual’s CVD and mortality 
risk profile. Several key features characterize this interaction. 1) High levels of CRF largely negate the 
adverse effects of excess adiposity, which is also referred as the ‘fat and fit’ phenomenon.8,85 2) Habitual 
physical inactivity is a significant contributor to the increased CVD risk in obese individuals since 
sedentary lifestyle is more prevalent in obese than leaner people.13 3) Exercise training (ET) and 
increased PA, with the goal of maintaining or improving CRF, are efficient and safe strategies for primary 
and secondary prevention of CVD in all weight groups. 
 CVD Risk Factors: Physically inactive obese individuals, compared to their physically active 
counterparts, are more likely to have insulin resistance and higher levels of adiposity-related 
inflammation. Lee et al. examined the relative and combined impact of changes in CRF and fatness on 
major CVD risk factors (HTN, MS, dyslipidemia) in the ACLS participants (n=3148, 6-year follow-up).119 
The investigators demonstrated an inverse association between CRF and the incidence of each outcome. 
Importantly, improving fitness attenuated, but not eliminated, the increased risks related to weight gain. 
Moreover, weight loss somewhat mitigated the increased risks associated with loss of CRF.120,121 
 CVD and Mortality: Several large-scale studies have confirmed the marked contribution of 
physical inactivity to the CVD risk in obese individuals. In the Nurse’s Health Study, obese and inactive 
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women were found to have 39% higher risk for CHD events and 62% greater risk of CVD mortality 
compared to obese women who were active.122,123 The adverse effects of obesity on coronary health 
were moderately attenuated, but not eliminated, by PA. And being lean did not counteract the CHD risk 
associated with physical inactivity.123 Physical inactivity usually shows a stronger association with 
abdominal obesity than BMI-based general obesity.124 However, the excess risk associated with physical 
inactivity appears to be more pronounced with general obesity than abdominal obesity.124 This 
differential impact was attributed to the possibility of more co-linearity between physical inactivity and 
abdominal obesity.13    
 Barry et al., in a meta-analysis of 10 prospective studies, examined the mutual influence of CRF 
and BMI on all-cause mortality.125 The investigators found that compared to fit individuals; unfit 
individuals had two times higher risk of death, regardless of BMI. Moreover, the mortality risk was 
similar for normal weight-fit, overweight-fit, and obese-fit individuals. Farrell et al., using the data from 
the CCLS (n=36,836 men), examined the additive effect of different adiposity components [BMI, WC, 
percent body fat([%BF)] and their interaction with CRF in the mortality risk.126 The authors observed 5%, 
37%, and 87% higher risk of death in individuals who were exposed to 1, 2, or 3 adiposity components, 
respectively, compared to those who did not have any exposure. And being fit was a predictor of 
improved survival within each of these four adiposity exposure groups. Moreover, adjustment of the 
results for BMI did not significantly alter the inverse association between exercise capacity and mortality 
risk. 
 Kenchaiah et al. examined the joint contribution of BMI and PA for the risk of incident HF in 
participants of the Physicians Health Study, a prospective cohort study of 21,000 men.127 The 
investigators observed that physical inactivity augmented the excess HF risk related to obesity. In fact, 
compared to the reference group (lean and active individuals), the risk of HF was higher by 49% in the 
overweight and active, 78% in the overweight and inactive, 168% in the obese and active, and 293% in 
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the obese and inactive groups. More recently, Pandey et al. examined the inter-relationship between 
BMI and objectively measured CRF in mid-life among participants of the CCLS (n=19,485) and 
demonstrated that mid-life CRF accounted for a significant proportion of BMI associated risk of HF in 
otherwise healthy adults. Furthermore, CRF change but not BMI change with aging was significantly 
associated with downstream risk of HF. Taken together, these findings highlight the important 
contribution of CRF towards obesity-related risk of HF.128  
Interaction of CRF and the Obesity Paradox 
Several studies have suggested that CRF significantly alters the prognostic implications of 
fatness in patients with CHD and HF.8,129 Key features of this interaction can be summarized as follows. 
1) Higher CRF is associated with improved outcomes in all weight groups, and the prognostic benefits of 
overweight/obesity disappear in fit patients. 2) The obesity paradox is usually limited to CHD and HF 
patients who are unfit. These findings highlight the more prominent role of CRF, compared to BMI, in 
determining the prognosis of patients with CVD.19 
CHD: Goel et al. examined the collective impact of CRF and adiposity parameters in 855 CHD 
patients referred for cardiac rehabilitation at the Mayo Clinic.47 Their analysis revealed a nearly three-
fold increased risk of mortality in subjects with low-CRF, even after adjustment for BMI and waist-to-hip 
ratio. The investigators observed an inverse association between BMI and risk of death only in subjects 
with low CRF but did not note a significant difference in mortality risk among fit individuals across 
different adiposity groups. McAuley et al. investigated the interaction of CRF and the obesity paradox in 
nearly 10,000 male ACLS participants with known or suspected CHD.130 The study demonstrated after 13 
years of follow-up that only those participants in the bottom tertile of age- and sex-related CRF had an 
obesity paradox which was present with BMI, WC, and %BF. However, among participants with high 
fitness (tertiles 2 and 3), no significant differences were observed in mortality risk across BMI, WC, %BF 
categories. Kokkinos et al. found in male veterans who were referred for exercise treadmill testing that 
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low BMI was associated with high mortality in only low-fit and moderate-fit subgroups, but not in those 
with high fitness.116 The authors concluded that CRF significantly affects the paradoxical BMI-mortality risk 
association and that lower BMI levels do not increase the risk for premature death as long as they are 
associated with high fitness. Moreover, their findings suggest that the paradoxically higher mortality risk 
observed with lower body weight as represented by lower BMI is likely the result of an unhealthy reduction 
in body weight and, perhaps most importantly, considerable loss of lean body mass. 
HF: Several studies have confirmed the substantial influence of CRF on the prognostic value of 
obesity in patients with HF.  Our research in a cohort of 2,066 patients with chronic HFrEF demonstrated 
that an obesity paradox was present only in HF patients with poor CRF (VO2max<14 ml/kg.min).
46 The 
worse outcomes were observed in leaner HF patients with poor CRF. Contrarily, individuals with high 
CRF had a better prognosis and were not affected by an obesity paradox (Figure 3). Clark et al. observed 
similar results in 1,675 HFrEF patients who underwent CPX at a single university center.131 Piepoli et al. 
reported a strong obesity paradox in 4,623 Italian patients with HFrEF referred for CPX.132 However, the 
prognostic differences between the BMI classes disappeared after inclusion of VO2max as a covariate; 
suggesting that the prognostic contribution of VO2max overwhelms that of BMI. Prognostic influence of 
CRF in HF patients with severe obesity (BMI≥40 kg/m2) is still not well known since these patients were 
either underrepresented or entirely excluded in studies.  
Zafrir et al. evaluated the collective impact of BMI and 6-minute walk distance (6MWD) in 543 
advanced HF patients.133 Consistent with other reports, the study showed a strong obesity paradox in 
the entire study population during 40 months follow-up. However, the obesity paradox disappeared in 
the high physical capability group, when study subjects were categorized based on 6MWD. As a novel 
approach, the authors also calculated the multiplication product of BMI and 6MWD (BMI*6MWD 
[kilogram/meter]). Compared to the lowest quartile of BMI*6MWD product, patients in the higher 
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quartiles had a declining pattern of mortality (31% lower in 2nd quartile, 36% lower in 3rd quartile, 60% 
lower in 4th quartile), after adjustment for other covariates (Figure 4).  
Mechanisms of CRF-Mediated Alteration in Risk and Prognosis of CVD in Obesity 
 Mechanisms of CRF-mediated alteration of CVD risk and prognosis in individuals with excess 
adiposity are still poorly understood. Several factors appear to play a role in the protective effects of 
high CRF and PA in overweight/obese individuals with known or at risk for CVD. As mentioned above, PA 
and higher CRF lower blood pressure and improve cardiometabolic risk profile which can explain, to 
some extent, the protective effects of high CRF in obesity.69–72 However, studies have repeatedly 
demonstrated that high CRF remains as the strongest predictor of improved outcomes in all weight 
groups even after adjustment for other major CVD risk factors, suggesting the potential contribution of 
several other mechanisms for CRF-related favorable results.  
 Body Composition:  Body fat distribution, particularly the distribution of excess visceral fat 
depots, is a strong predictor of CVD, independent of total adiposity.134 Exercise training can substantially 
influence the body fat distribution.135 Fit individuals tend to have less amount of visceral fat depots 
compared to unfit individuals with same BMI.136 Johnson et al. reported that aerobic ET for 4 weeks 
resulted in a significant reduction in hepatic lipid concentration even in the absence of any changes in 
the body weight or WC.137 In a meta-analysis of 15 small size studies (n=852), ET markedly reduced the 
volume of visceral adipose tissues at varying degrees depending on gender, and the type and intensity of 
training.138  
ET and PA strongly correlate with increased muscle mass and strength which are some of the 
hallmark findings of high CRF.139,140 Increased muscle mass and strength predicts improved outcomes in 
patients with CVD. For instance, in a retrospective cohort of 771 Japanese patients with acute HF, 
Kamiya et al. found a strong, independent association between muscle mass (assessed with mid-upper 
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arm circumference) and improved survival.44 Moreover, muscle mass was found to have a 
complementary prognostic value in HF patients when added to BMI (Figure 5). In contrast, sarcopenia 
and decreased amount of appendicular lean mass are considered as significant predictors of poor 
outcomes in the general population and CVD patients, regardless of BMI.19 Sarcopenia is a common 
condition in older adults and those with chronic diseases. 141 In the general population, sarcopenic 
obesity was associated with a 24% higher risk of mortality compared to non-sarcopenic obesity.142 
Sarcopenia has been linked to impaired exercise capacity, muscle strength and quality of life in patients 
with HFpEF.141 We still need further research to identify the potential mechanisms underlying the link 
between muscle mass and CVD prognosis. 
 Insulin Resistance: Insulin resistance is implicated in the pathogenesis of several CVD risk factors 
and diseases such as T2DM, HTN, HF, etc. PA and ET substantially alter obesity-related insulin resistance. 
In the Multi-ethnic Study of Atherosclerosis, PA was found to have a strong inverse correlation with 
insulin resistance.121  
Inflammation: Low-grade chronic inflammation due to excess adiposity is a major contributor to 
the CV risk profile and disease prognosis.85 And obesity-related inflammation, assessed by the levels of 
cytokines and adipokines, has been shown to decrease in response to PA.120 Moreover, increased CRF 
was associated with lower levels of white blood cell counts in patients with MS, suggesting an 
attenuated inflammatory response in fit individuals.143 
 Hematologic: Excess adiposity has been linked to increased platelet reactivity, which potentially 
contributes to the increased CV event risk in overweight/obese individuals.144 Keating et al., in a small 
prospective randomized study of overweight subjects with CHD, demonstrated that four months of ET 
and weight loss resulted in a significant decline in platelet reactivity.145 
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 Endothelial Dysfunction: Obesity-related endothelial dysfunction plays a role in the 
pathogenesis of CVD. There exists substantial evidence from animal studies regarding the beneficial 
impact of exercise on obesity-related endothelial dysfunction.146 A small study (n=42) by La Favor et al. 
recently demonstrated that eight weeks of exercise in obese individuals reduced endothelial dysfunction 
to levels similar to that of lean individuals.147  
Oxidative Stress: Oxidative stress is involved in the pathogenesis of insulin resistance, type-2 
DM, and CVD. Bianchi et al. found that a structured program of nutrition and ET for 12 weeks, when 
accompanied by weight loss and improved CRF, resulted in a marked decline of reactive oxygen species 
in sedentary individuals with obesity.148  
Conclusions  
Overweight and obesity are well-established risk factors for most CVDs, including CHD, HF, and 
AF. Despite the strong link between excess adiposity and risk of CVD, overweight and mildly obese 
patients with CVD usually have a better prognosis than their leaner counterparts. This obesity paradox is 
now a well-established phenomenon across different types of CVDs, and it occurs regardless of age and 
ethnicity of patients and severity of CVD.  
Physical inactivity and low CRF are major risk factors for CVD. Numerous studies have confirmed 
that being normal-weight is not synonymous with being healthy. Because unfit normal-weight 
individuals usually have a higher risk of all-cause and CVD mortality than normal-weight fit individuals 
and in some cases even compared to obese but fit people.149 Despite its strong prognostic role in CVD 
and mortality risk, CRF is often underutilized as a CVD risk factor, because of difficulties in measuring 
CRF and lack of widely accepted definition and staging of CRF.85  Indeed, CRF significantly modifies the 
relationship between adiposity and mortality in the general population and individuals with known CVD. 
Increased PA and higher CRF are significant predictors of improved CVD outcomes in all BMI groups. 
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Several studies have shown that prognostic implications of obesity disappear in fit CVD patients and the 
obesity paradox mainly affects those with low CRF. 
Regular PA and structured ET constitute a fundamental aspect of non-pharmacological 
management of patients with or at risk for CVD. From a primary prevention standpoint getting patients 
out of their sedentary behaviors can provide the most benefit regarding prevention of the onset of 
CVDs.13 There also exists robust evidence for the efficacy of ET as a therapy for secondary prevention in 
patients with established CVD. A meta-epidemiological study by Naci et al. which included 305 studies 
with nearly 340,000 participants demonstrated that ET interventions were at least as effective as many 
drug therapies for secondary prevention of CHD, HF and DM.150 ET in patients with CVD should ideally 
include both aerobic-type exercise to increase overall CRF and skeletal muscle training, and resistance 
ET to maintain lean muscle mass and improve muscular fitness.19,45 
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Figure/Table Legends 
Table: 
Title: Mechanism of the Obesity Paradox in CVD 
 
Figure 1: 
Title: Outcomes of AF Freedom According to CRF Gain and Weight Loss 
Caption: Kaplan-Meier curve for total AF-free survival (multiple ablation procedures ± drugs) according 
to weight and CRF trends in 1,415 patients with AF. AF, atrial fibrillation; MET, metabolic equivalent; WL, 
weight loss. Reprint from Pathak et al. with permission from the publisher.102 
 
Figure 2: 
Title: Adjusted Risk for Major Adverse CV Events According to Fitness Categories in US Veterans 
Caption: The bar graph demonstrates the adjusted hazard ratios for major adverse CV events (during 11 
years of follow-up) according to fitness categories in comparison to the reference group (least fit 
subjects). CRF categories were determined based on age-specific predicted CRF thresholds. The figure 
was drawn based on data from Kokkinos et al..106 
 
Figure 3: 
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Caption: Kaplan-Meier analysis according to BMI categories in the low-CRF group (oxygen consumption 
<14 mL O2/kg.min) (A) and the high-CRF group (oxygen consumption ≥14 mL O2/kg.min) (B). BMI, body 
mass index. Reprint from Lavie et al. with permission from the publisher.46 
 
Figure 4: 
Title: Joint Impact of BMI*SMWD Product on Mortality 
Caption: Adjusted hazard ratio for all-cause mortality according to the product of BMI and physical 
capacity assessed by the SMWD test. SMWD, six-minute walk distance. The image was drawn based on 
data from Zafrir et al.133  
 
Figure 5: 
Title: Combined Impact of BMI and Muscle Mass in Heart Failure 
Caption: Kaplan-Meier curve for survival according to combined BMI and MUAC categories in patients 
with HF. BMI, body mass index; MUAC, mid-upper arm circumference. Reprint from Kamiya et al. with 
permission from the publisher.44 
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Table: Mechanisms of the Obesity Paradox in CVD 
Increased muscle mass and strength 
Implications related to CRF 
Higher energy reserves 
Better nutritional status 
Earlier presentation of CVD 
Compression of morbidity in lean individuals 
Reverse epidemiology of detrimental effects of cachexia and 
frailty 
Better tolerability of CVD medications 
Genetic factors 
Changes in cytokines and neuroendocrine profiles 
Immune modulation 
Mitochondrial function augmentation 
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